Abstract Human metallothioneins, small cysteine-and metal-rich proteins, play an important role in the acquired resistance to platinum-based anticancer drugs. These proteins contain a M(II) 4 (CysS) 11 cluster and a M(II) 3 (CysS) 9 cluster localized in the a-domain and the b-domain, respectively. The noninducible isoform metallothionein-3 (Zn 7 MT-3) is mainly expressed in the brain, but was found overexpressed in a number of cancer tissues. Since the structural properties of this isoform substantially differ from those of the ubiquitously occurring Zn 7 MT-1/Zn 7 MT-2 isoforms, the reactions of cis-diamminedichloridoplatinum(II) (cisplatin) and trans-diamminedichloridoplatinum(II) (transplatin) with human Zn 7 MT-3 were investigated and the products characterized. A comparison of the reaction kinetics revealed that transplatin reacts with cysteine ligands of Zn 7 MT-3 faster than cisplatin. In both binding processes, stoichiometric amounts of Zn(II) were released from the protein. Marked differences between the reaction rates of cisplatin and transplatin binding to Zn 7 MT-3 and the formation of the Pt-S bonds suggest that the binding of both Pt(II) compounds is a complex process, involving at least two subsequent binding steps. The electrospray ionization mass spectrometry characterization of the products showed that whereas all ligands in cisplatin were replaced by cysteine thiolates, transplatin retained its carrier ammine ligands.
Introduction cis-Diamminedichloridoplatinum(II) (cisplatin) is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors, such as ovarian, testicular, and bladder tumors. Cisplatin is also used in combination with radiotherapy or surgical treatment [1] . The cytotoxic mode of action is mediated by its binding mainly to two adjacent purine bases of nuclear DNA, forming primarily intrastrand cross-links. This DNA modification distorts the DNA structure such that translation and excision repair is strongly inhibited, directing cells into apoptosis or necrosis [2, 3] .
A geometrical isomer of cisplatin, trans-diamminedichloridoplatinum(II) (transplatin), is clinically inactive. This is believed to be due mainly to its inability to form similar DNA adducts as cisplatin [4] . The resistance of cancer cells to Pt(II) drugs can be either intrinsic or acquired following Pt(II) administration [1] . The acquired resistance after initial treatment is the major drawback of these chemotherapeutics. Because of the strong reactivity of Pt(II) compounds toward sulfur-donor molecules and the formation of very stable Pt-S bonds, intracellular thiols through their competition with DNA confer resistance to antitumor platinum drugs. The abundant intracellular thiols involved in the drug resistance are glutathione (GSH) and metallothionein (MT) [1, 5, 6] . The four MT isoforms expressed in humans (designated MT-1 through MT-4) consist of 61-68 amino acid residues, of which 20 are conserved cysteines. The structural studies revealed that MTs bind seven Zn(II) or Cd(II) through cysteine thiolates forming two metal-thiolate clusters: a M(II) 3 S 9 cluster located in the b-domain and a M(II) 4 S 11 cluster in the a-domain of the protein [7] . The ubiquitously occurring MT-1 and MT-2 isoforms are inducible by a variety of compounds, including hormones, cytokines, and metal ions, including Pt(II) drugs. These proteins are involved in the zinc and copper homeostasis, heavy metal detoxification, immune system function, and protection from apoptosis [8] [9] [10] [11] . Although GSH effectively deactivates cisplatin and in the certain cancer cell lines its cellular concentration increases upon exposure to Pt(II) drugs, thiols of MTs react faster with cisplatin compared with GSH [12, 13] . In cancer cells basal MT-1/MT-2 expression levels are often significantly increased, resulting in an even stronger Pt(II) scavenging effect [14, 15] . The overexpression of MT-1/MT-2 isoforms in response to Pt(II) drug administration is responsible for most of the cases of acquired resistance to cisplatin [15] [16] [17] . In our previous studies we showed that the rates of Zn 7 MT-2 reaction with cis-[Pt(N-donor) 2 Cl 2 ] and trans-[Pt(N-donor) 2 Cl 2 ] compounds depend on the nature of the coordinated ligands and that trans-[Pt(N-donor) 2 Cl 2 ] compounds react faster. In this reaction, owing to the high affinity of Pt(II) for cysteine thiolates, exceeding that of Zn(II) 10 7 times, Zn(II) is substituted by Pt(II) [18, 19] . The characterization of the products showed that whereas all ligands in cis-Pt(II) compounds were replaced by cysteine thiolates, trans-Pt(II) compounds retained their nitrogen-donor ligands.
The MT-3 isoform (Zn 7 MT-3), also termed ''neuronal growth inhibitory factor,'' occurs intra-and extracellularly and shows neuroinhibitory activity in vitro that distinguishes it from the widely expressed Zn 7 MT-1 and Zn 7 MT-2 isoforms. MT-3 shows a brain-specific expression, mainly in glutamatergic neurons [20] [21] [22] [23] . This isoform is unresponsive to the inducers of MT-1 and MT-2 expression mentioned above [24] . However, MT-3 was found overexpressed in a number of cancers, such as prostatic adenocarcinoma, esophageal cancer, and breast cancer, where its presence positively correlates with the poor survival prognosis after platinum chemotherapy [22, [25] [26] [27] . Furthermore, since MT-3 is absent in normal bladder tissues but is present in large amounts in bladder cancer, the use of this isoform as a marker of this disease has been suggested [28] . The changes in the primary structure of MT-3, which include a unique C(6)PCP(9) motif in the b-domain and an acidic hexapeptide insert in the a-domain (Fig. 1) , translate into widely different structural properties of Zn 7 MT-3 compared with Zn 7 MT-1/Zn 7 MT-2 [7, 29] . Thus, the Zn 7 MT-3 structure is highly dynamic and the thiolate ligands possess a substantially higher nucleophilicity, indicated by their reactivity toward a number of compounds, including 5,5 0 -dithiobis(2-nitrobenzoic acid) and S-nitrosothiols [30] [31] [32] . However, the reactivity of Zn 7 MT-3 toward cisplatin and the products formed is not known.
In the present work, the reactions of Zn 7 MT-3 with cisplatin and transplatin were investigated and the products characterized by electrospray ionization mass spectrometry (ESI-MS) and 113 Cd NMR. The studies were conducted under nativelike conditions regarding pH, ionic strength, and a Pt(II) to Zn 7 MT ratio of 2:1 relevant to in vivo studies [18, 33] . The results obtained were compared with those obtained with Zn 7 MT-2. The biological implications of these studies for the acquired resistance to platinum-based drugs are discussed.
Materials and methods

Expression and purification of MTs
Recombinant human MT-3 and MT-2 were expressed in Escherichia coli as Cd(II) proteins and purified essentially as described in [18, 34] . The correctness of the protein Fig. 1 Alignment of amino acid sequences of human metallothionein-2 (MT-2) and metallothionein-3 (MT-3) isoforms used in this study. Cysteine residues are highlighted in gray expression was verified by ESI-MS at low pH. Single mass peaks of 6,925.7 Da (calculated 6,927.1 Da) and 6,041.0 Da (calculated 6,042.1 Da) corresponding to metal-free MT-3 and MT-2, respectively, were obtained. The protein purity was further assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis [35] . The concentration of reduced thiols was determined by 2,2 0 -dithiodipyridine assay [36] . In all cases, a cysteine to protein ratio of 20.0 ± 0.5 was obtained. Fully Zn(II) loaded or Cd(II) loaded MTs were prepared by reconstitution as described in [37] . Metal-to-protein ratios were determined by measuring the metal content by flame atomic absorption spectrometry (SpectrAA-110, Varian) in 15 mM HNO 3 [38] and that of the protein spectrophotometrically in 0.1 M HCl (e 220 = 53,000 M -1 cm -1 for MT-3 and 48,200 M -1 cm -1 for MT-2) [36] . In all cases, a metal-toprotein ratio of 7.0 ± 0.3 was obtained.
Platinum quantification by atomic absorption spectrometry
Cisplatin and transplatin were purchased from Sigma (USA). Prior to use, aqueous solutions (300-500 lM) of both compounds were kept in the dark at room temperature for at least 1 day and further at 4°C. The Pt(II) solutions were freshly prepared after 1-2 months. The Pt(II) concentrations in the stock solutions and experimental samples were determined by flameless atomic absorption using a Varian AA240FS fast sequential atomic absorption spectrometer (Varian, Australia) equipped with a GTA120 graphite tube atomizer and a PSD120 programmable sample dispenser. Prior to analysis, the samples were diluted in15 mM HNO 3 .
Characterization of Pt,ZnMT species by ESI-MS Samples of 10 lM Zn 7 MT-2/Zn 7 MT-3 or Cd 7 MT-2/ Cd 7 MT-3 were incubated in a nitrogen-purged glove box with 2 mol equiv of cisplatin and transplatin in 10 mM N-(2-hydroxyethyl)piperazine-N 0 -ethanesulfonic acid (HEPES)/ NaOH pH 7.4, 100 mM NaClO 4 for 120 h. Subsequently, unbound Pt(II) compounds were removed and the solvent was simultaneously exchanged by passing it through a 5- . ESI-MS analysis of the protein-containing solution was performed using a Q-TOF Ultima API mass spectrometer (Micromass, UK) essentially as described for MT-2 in our previous work [18] . Solutions were infused through a fused silica capillary (inner diameter 75 lm) at a flow rate of 0.5 lL min -1 . Electrospray Pico Tips (inner diameter 30 lm) were obtained from New Objective (Woburn, MA, USA). Mass spectra were acquired by scanning an m/z range from 600 to 2,500 with a scan duration of 1 s and an interscan delay of 0.1 s. The spray voltage was set to 2.1 kV, the cone voltage to 50 V, the RF lens to 1, the energy to 50 V, and collision to 15. Mass spectra were deconvoluted using the MaxEnt 1 software program (Micromass, UK).
Kinetics of cisplatin and transplatin binding to Zn 7 MT-2/Zn 7 MT-3
The binding of cisplatin and transplatin to Zn 7 MT-2 and Zn 7 MT-3 was monitored by absorption spectroscopy following the Pt-S ligand to metal charge transfer band at 285 nm [39] . Prior to measurements, the proteins in 10 mM HEPES/NaOH pH 7.4, 100 mM NaClO 4 , and water solutions of cisplatin or transplatin were rendered oxygen-free by three freeze-pump cycles on the vacuum line and placed into a nitrogen-purged glove box in the dark at 4°C. An aliquot of 960 lL of the 10 lM protein solution was quickly mixed with 40 lL of 500 lM Pt(II) compound in a quartz cuvette and the cuvette was sealed.
The time courses of the reactions were followed spectrophotometrically (Ultrospec 2000, Amersham Biosciences) at 285 nm at 37°C for 120 h. The data were normalized per Pt-S bond using e 285 nm of 2,680 M -1 cm -1 and fitted using the Origin 7.0 software package [18] .
Quantification of platinum bound to MT-3
The proteins were mixed and incubated with the Pt(II) compounds using the conditions described for the kinetics of platinum binding. Aliquots of 200 lL were withdrawn after 0, 2, 5, 18, and 120 h of sample incubation. The aliquots were applied to Microcon YM-3 (Millipore, USA) concentrators and the low molecular weight fraction was separated and the concentration of unbound Pt(II) was determined by atomic absorption. The concentration of Pt(II) bound to the protein was calculated by subtracting the determined Pt(II) concentration from its initial concentration in the sample. No evidence for the interaction of free Pt(II) compounds or platinated MTs with Microcon membranes was obtained in control experiments.
Kinetics of Zn(II) release from Zn 7 MT-3 upon Pt(II) binding
To monitor Zn(II) release from Zn 7 MT-2/Zn 7 MT-3, experiments were carried out using the conditions described for the Pt(II) binding to the thiolates of Zn 7 MT-2/ Zn 7 MT-3 and in the presence of 10 lL of 10 mM 2-carboxy-2 0 -hydroxy-5 0 -sulfoformazylbenzene sodium salt (zincon), dissolved in 10 mM NaOH. The concentration of released Zn(II) was monitored through changes in the absorption of the Zn(II)-zincon complex at 620 nm (e 620 nm = 23,200 M -1 cm -1 ) with time [40] . 113 Cd NMR of Pt 1 113 Cd 6 MT-3 113 Cd NMR spectra (110.9 MHz) were recorded with a Bruker DRX-500 spectrometer using inverse-gated broadband proton decoupling to account for possible negative 113 Cd, 1 H nuclear Overhauser effects. Data were sampled over a 62,500-Hz spectral width using a 0. 
Results
Characterization of platinated MT-3 species formed with cisplatin and transplatin
In vivo studies have shown that the administration of cisplatin or transplatin to rabbits results in the formation of Pt *2 Zn *5 MT species in liver and kidneys [33] . Therefore, in our studies the binding of 2 mol equiv of cisplatin or transplatin to Zn 7 MT-3 was investigated. Owing to the low intracellular Cl -concentration (4-23 mM), the cis-[Pt(NH 3 ) 2 Cl 2 ] complex will hydrolyze after entering the cell to form cis-[Pt(NH 3 ) 2 
(X is OH -, H 2 O; a = 0, 1) and, to a smaller extent, cis- [41, 42] . To mimic this situation, cisplatin and transplatin were dissolved in H 2 O and allowed to hydrolyze for at least 1 day at ambient temperature [18] . The exchange of the leaving ligands is essential for the reaction of Pt(II) compounds with DNA. However, no influence of the aquation/anation degree on the reactivity of Pt(II) compounds toward MTs and other thiols such as GSH or cysteine was observed previously [43] [44] [45] . To characterize the final products of the reaction of human Zn 7 MT-3 with cisplatin and transplatin, the previously developed ESI-MS method was used [18] . The protein was incubated with both Pt(II) compounds for 120 h in 10 mM HEPES/NaOH, pH 7.4, 100 mM NaClO 4 , at 37°C. These buffer conditions were used in all kinetic studies. To exclude cysteine oxidation by air oxygen during the prolonged sample incubation, experiments were performed under anaerobic conditions. After incubation, the protein was transferred into 10 mM 4-ethylmorpholine/HOAc, pH * 7 buffer and analyzed by ESI-MS (Fig. 2) . Similar ESI-MS spectra, showing the same pattern of masses with substantially lower intensity, were also obtained after 5-h sample incubation (data not shown). This observation is in good agreement with our previous time-dependent ESI-MS studies of the interaction of Pt(II) complexes with human Zn 7 MT-2 [18] .
Since the sum of the molecular masses of three zinc atoms (196.11 g mol -1 ) is, considering the accuracy of the method, very close to the molecular mass of one platinum atom (195.09 g mol -1 ), the mass spectra were simultaneously recorded also at pH * 3 (Fig. 2a, b) . Under these conditions Zn(II), but not Pt(II) is released from the protein.
The deconvoluted ESI-MS spectrum of PtMT-3 complexes with cisplatin obtained at pH * 3 reveals mass peaks of 7,118.6, 7,311.8, and 7,505.0 Da, which we assigned to the MT-3 species containing one, two and three Pt(II) bound to the protein, respectively (Fig. 2a) (Fig. 2b) . Thus, transplatin preserves its ammine ligands in complex with MT-3. A comparison of the relative intensities of the mass peaks at low pH reveals that the PtMT-3 complexes containing one and two Pt(II) are mainly formed ( Table 1) .
The ESI-MS spectra obtained at pH * 7 were more heterogeneous (Fig. 2c, d ). In addition to the species of the Pt x Zn 7-x MT-3 (x = 1 -3) type, a minor population of Pt x Zn 8-x MT-3 (x = 1 -4) complexes was also formed ( Table 1) . The formation of similar complexes with cisplatin and transplatin was also seen in our previous studies of Zn 7 MT-2 [18] .
Kinetics of cisplatin and transplatin binding to thiols of Zn 7 MT-3
The reactivity of cisplatin and transplatin toward the cysteines of Zn 7 MT-3 was also investigated. As the platinum-to-MT ratio of 2 was applied in our studies, the pseudofirst-order conditions cannot be fulfilled. Therefore, to allow the comparison of the apparent initial rates of the reactions involving cisplatin and transplatin, the experimental conditions were kept identical. The formation of Pt-S bonds in MT-3 with time was followed by absorption spectroscopy for 120 h to allow almost complete reaction. The results obtained were normalized per Pt-S bond using the extinction coefficient of 2,680 M -1 cm -1 at 285 nm [18] . The kinetic traces of the reaction of Zn 7 MT-3 with 2 mol equiv of cisplatin or transplatin show a biphasic Fig. 2 Deconvoluted electrospray ionization mass spectrometry spectra of Zn 7 MT-3 upon the reaction with 2 mol equiv of a, c cisplatin or b, d transplatin in 10 mM N-(2-hydroxyethyl)piperazine-N 0 -ethanesulfonic acid (HEPES)/ NaOH pH 7.4, 100 mM NaClO 4 for 120 h at 37°C. The masses of the observed species are given in Table 1 profile characterized by a fast initial phase followed by a slow second phase (Fig. 3a) . The atomic absorption data revealed that the final products of the reaction were complexes with an overall stoichiometry of Pt 2 Zn 5 MT-3. In these species up to approximately seven Pt-S bonds were formed with cisplatin and approximately 3.5 Pt-S bonds with transplatin. The higher number of Pt-S bonds formed with cisplatin suggests that both ammine ligands were replaced, resulting in a Pt(CysS) 4 coordination. In contrast, the presence of nearly 3.5 Pt-S bonds with transplatin suggests that a Pt(NH 3 ) 2 (CysS) 2 species is formed. These results are in agreement with the ESI-MS data presented above. From the initial slopes of the kinetic traces, the apparent initial rates k obs were derived and compared (Fig. 3b) . The value of 22.6 9 10 -4 min -1 obtained for the reaction of MT-3 with transplatin is higher than that determined for cisplatin (k obs = 20.2 9 10 -4 min -1 ). Thus, the reaction of both Pt(II) compounds with Zn 7 MT-3 is about twice as fast as with Zn 7 MT-2 [18] .
Kinetics of cisplatin and transplatin binding to Zn 7 To investigate the rates of cisplatin and transplatin reaction with Zn 7 MT-3 and, for comparison also with Zn 7 MT-2, we determined free Pt(II) concentrations in the reaction mixture as a function of time under identical experimental conditions. The proteins were anaerobically incubated with 2 mol equiv of Pt(II) compounds in 10 mM HEPES/NaOH pH 7.4, 100 mM NaClO 4 at 37°C for up to 120 h. At different time intervals, aliquots of the incubation mixture were applied to Microcon YM-3 concentrators (molecular mass cutoff 3 kDa) and the low molecular mass components were separated. The concentration of free Pt(II) present in the filtrate was determined by atomic absorption. The amount of cisplatin and transplatin bound to Zn 7 MT-2/ Zn 7 MT-3 was obtained by subtracting the free Pt(II) concentration from the initial Pt(II) concentration. These values, normalized per protein concentration, are shown in Fig. 4 .
The kinetics presented in Fig. 4 show a biphasic profile of Pt(II) binding to Zn 7 MT-3. A comparison of the rapid initial kinetic phases of the reaction showed that transplatin reacts with Zn 7 MT-3 about 1.6 times faster than cisplatin. After 5-h incubation, a slow binding phase sets in with only minor concentrations of free Pt(II) compounds after 120-h incubation. Specifically, from the 2 mol equiv of cisplatin and transplatin initially added to Zn 7 MT-3 about 1.98 mol equiv was bound to the protein. Compared with Zn 7 MT-3, Zn 7 MT-2 reacts with both cisplatin and transplatin on average about 1.5 times slower during the first 5 h of reaction (Fig. 4) . The release of Zn(II) upon Pt(II) binding to Zn 7 MTs is a direct consequence of the competition between these metals for cysteine thiolates. The kinetics of Zn(II) release was examined using the conditions described for the reaction of cisplatin and transplatin with cysteine thiolates and in the presence of the Zn(II)-chelating dye zincon. The 1:1 Zn(II)-zincon complex formed, which is characterized by an absorption maximum at 620 nm (e 620 nm = 23,200 M -1 cm -1 ) [40, 46] , was used to monitor Zn(II) release. Prior to these experiments, the absence of a complex between zincon and Pt(II) was established. The results show that around 1.8 mol equiv of Zn(II) was released from Zn 7 MT-3 after 120-h incubation with 2 mol equiv of cisplatin and transplatin (Fig. 5a ). This indicates that Pt(II) binding leads to displacement of the corresponding number of mole equivalents of Zn(II) from the protein. As judged from the initial slopes of the fast reaction phase, transplatin with k Moreover, the apparent rates of release of Zn(II) from Zn 7 MT-3 are about twice as fast as those from Zn 7 MT-2 (Fig. 5b) . A comparison of k obs for the Pt-S bond formation (Fig. 3b) and Zn(II) release (Fig. 5b) reveals that the Zn(II) release from Zn 7 MT-3 and Zn 7 MT-2 is roughly twice as fast. This likely reflects the strong labilization of Zn(II) in the cluster structure induced by the breaking of even a single Zn-S bond. Although in all kinetic studies a simple hyperbolic dependence was obtained, the reactions are more complex and follow higher-order kinetics. Evidence comes from the ESI-MS data in which the formation of different products was seen (Fig. 2) . 113 Cd NMR characterization of Pt 1 113 Cd 6 MT-3
To reveal whether the a-domain or the b-domain of MT-3 is preferentially reacting with cisplatin, we applied 113 Cd NMR spectroscopy. Previously, a close similarity between the structures of Zn(II)-and Cd(II)-containing metalloforms of M 7 MT-2 was demonstrated [7] . Prior to NMR measurements, the additional ESI-MS experiments established that in the reaction of Cd 7 MT-3 with 1 mol equiv of cisplatin heterogeneous Pt x Cd 7-x MT-3 (x = 1 -3) complexes lacking ammine ligands, seen also with Pt,ZnMT-3, were formed (data not shown). For 113 Cd NMR measurements 113 Cd 7 MT-3 was incubated with 1 mol equiv of cisplatin in 10 mM HEPES/NaOH pH 7.4, 100 mM NaClO 4 for 120 h. The Pt 1 113 Cd 6 MT-3 sample was then concentrated to about 3 mM and brought into 15 mM potassium phosphate/sodium phosphate buffer pH 7.3. The 113 Cd NMR spectra of Pt 1 113 Cd 6 MT-3 and 113 Cd 7 MT-3 are shown in Fig. 6 . Cd couplings, and a markedly reduced and temperature-independent intensity (20%) of the resonances of the Cd 3 cluster. These features have been interpreted in terms of dynamic processes acting on two different NMR time scales: fast exchange processes among conformational cluster substates occurring in both clusters and additional slow exchange processes among configurational cluster substates in the Cd 3 cluster [48] . The latter exchange processes allowed only the structure of the a-domain of 113 Cd 7 MT-3 to be determined by NMR [47] .
In the spectrum of Pt 1 113 Cd 6 MT-3, the three-metalcluster resonances are virtually absent (Fig. 6) . The perturbation of the four-metal-cluster resonances by Pt(II) binding was only minor. This was characterized by a broadening of the 113 Cd resonance VII and a small lowfield shift of the 113 Cd resonance VI from 622 to 623 ppm, resulting in its overlap with resonance V (Table 2) .
This suggests that Pt(II) is preferentially bound to the more dynamic three-metal cluster. Furthermore, no other 113 Cd resonances were detected between 900 and 350 ppm. The monomeric nature of the Pt 1 113 Cd 6 MT-3 sample after NMR measurements (72 h) was confirmed by analytical gel filtration in which the presence of about 10-15% of dimers was detected.
Discussion
The present study provides insights into the reaction of human Zn 7 MT-3 with cisplatin and transplatin and the products formed. The fate of the Pt(II) complexes in the cells is kinetically controlled and will depend on the accessibility of cysteine thiolates for electrophilic attack. In mammalian MTs both metal-thiolate clusters are buried in the protein structure. When compared with the structures of the Zn 7 MT-1/Zn 7 MT-2 isoforms, the structure of Zn 7 MT-3 is more flexible and both metal-thiolate clusters show reduced metal affinity. These structural properties are responsible for the higher reactivity of nucleophilic sulfhydryl groups in Zn 7 MT-3 with electrophiles such as 5,5 0 -dithiobis(2-nitrobenzoic acid) [31] . In this regard, the three-metal cluster in the b-domain has been shown to be more reactive than the four-metal cluster in the a-domain. In our 113 Cd NMR studies of Pt 1
113
Cd 6 MT-3, a similar preferential reactivity of the Cd 3 cluster with cisplatin was also seen. The virtual absence of the 113 Cd resonances of the Pt(II)-modified Cd 3 cluster in the b-domain presumably reflects a low population of (Pt,Cd) 3 complexes with varying Pt(II) distributions. This conclusion is supported by ESI-MS analysis of the product of the reaction of Cd 7 MT-3 with 1 mol equiv of cisplatin, showing the formation of complexes with platinum-to-MT ratios between 1 and 3. The results obtained differ from the results of the similar 111 Cd NMR studies of rabbit 111 Cd 7 MT-2 where a cooperative cisplatin binding to the three-metal cluster was reported [49] . A number of studies showed that both protein domains in MT-3 interact with each other [50, 51] . Thus, a small perturbation of the Cd 4 -cluster resonances, including a broadening of the cadmium VII resonance and a small low-field shift of the cadmium VI resonance, most likely originates from the changes in the cross-talk between both protein domains brought about by Pt(II) binding to the b-domain.
The characterization of the final products of the reaction of Zn 7 MT-3 with 2 mol equiv of cisplatin or transplatin resulted in a species with overall stoichiometry of Pt 2 Zn 5 MT-3. In these species an average of seven Pt-S bonds were formed with cisplatin and 3.5 Pt-S bonds with transplatin. These results and the ESI-MS data indicate that whereas in the reaction of Zn 7 MT-3 with cisplatin both carrier and leaving ligands are lost, the carrier NH 3 ligands in transplatin were retained. The trans-effect labilization of the carrier NH 3 ligands in cisplatin trans to CysS accounts for the generation of Pt(II)(SCys) 4 complexes in Pt 2 Zn 5 MT-3. The kinetic profiles of cisplatin and transplatin binding to Zn 7 MT-3 reveal that about 1.7 mol equiv of both Pt(II) compounds is bound to MT-3 already after 5 h. In marked contrast, at the same time point only about half of the total Pt-S bonds developed and 1 mol equiv of Cd NMR spectra were recorded in 15 mM potassium phosphate/sodium phosphate buffer, pH 7.3 at 50°C
The numbers are relative to the integrated intensity of peak I Zn(II) was released. These results suggest that the binding of Pt(II) complexes to the three-metal cluster in the bdomain is a complex process, involving at least two subsequent kinetic phases. This process could be interpreted as initial binding of Pt(II) complexes to a reduced number of thiolate groups (one or two). The subsequent saturation of Pt(II) coordination sites by additional thiolate ligands would then introduce substantial changes in the domain structure accompanied by the release of the second mole equivalent of Zn(II). Furthermore, as MT-3 contains 11 carboxylate donor ligands, representing a kinetically attractive first protein coordinating site for cisplatin and transplatin at pH 7.4, their possible involvement in the initial binding step cannot be ruled out. In recent studies of the binding of cisplatin to cellular DNA-binding proteins similar platinum coordination sites have been identified [52] .
While the expression of the MT-1/MT-2 isoforms is induced by toxic Cd(II) and Pt(II), the MT-3 expression is unresponsive to these inducers. The exposure to these metal ions results in their scavenging in the cytosol by Zn 7 MTs and Zn(II) release. As the expression of MT-1/ MT-2 is regulated by zinc responsive transcription factor 1 (MTF-1), the released Zn(II), through activation of this factor, leads to overexpression of MT-1/MT-2 [53, 54] . Activated MTF-1 also regulates the expression of other proteins such as c-glutamylcysteine synthetase, zinc transporter 1, and a-fetoprotein. The enzyme c-glutamylcysteine synthetase is involved in the biosynthesis of GSH, another sulfur-containing compound involved in the Pt(II) resistance. As MTF-1 is not involved in the regulation of MT-3 expression, the induction of this MT isoform by free Zn(II) will not take place [55] . However, in recent studies the MT-3 gene was identified as hypoxia-inducible in several human tissues [56] [57] [58] . Therefore, we suggest that overexpression of MT-3 observed in several cancers is a result of the hypoxic conditions, due to insufficient vascularization of the fast-proliferating tissue.
The MT-3 isoform has an increasing significance as a diagnostic marker of bladder [28] and esophageal [27] cancers and its presence in these and several other cancers tightly correlates with the poor chemotherapy outcome [25, 26, 59] . The degree of MT-based acquired resistance to Pt(II) drugs may depend on the specific expression pattern of MT isoforms. The data presented suggest that in frequent situations of the overexpression of several MT isoforms in the cancer tissues [17] , the reaction of administered Pt(II) drugs with MT-3 would be kinetically preferred. The released Zn(II) in this process and its binding to MTF-1 would then result in the upregulation of the MT-1/MT-2 expression.
